With 14 new gene therapy approvals in the last 18 months, billion-dollar collaborations, and the development of treatments for more common conditions, the gene therapy field is rapidly gaining momentum and broadening scope beyond rare diseases.
For the first time, this industry-defining meeting will reflect the field’s growing focus on developing therapies for common diseases, whilst addressing existing hurdles in rare and ultra-rare disorders. This is your unparalleled opportunity to delve into:
- The latest global regulatory requirements
- Optimizing routes for CNS
- Ocular and inner ear disorders
- Innovations in capsid engineering and dosing strategies
- Increasing volumetric productivity to reduce CoGs
Secure your place here or get in touch with the team – info@hansonwade.com